Drug Profile
BMS 754807
Alternative Names: BMS-754807Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Pyrazoles; Small molecules
- Mechanism of Action Insulin-like growth factor-I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Solid tumours
Most Recent Events
- 10 Apr 2021 Pharmacodynamics data from a preclinical study in Breast cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 17 Jun 2013 Bristol-Myers Squibb terminates in its phase I/II trial for Solid tumours (combination therapy) in USA & Canada (NCT00908024)
- 30 Apr 2013 Bristol-Myers Squibb completes a phase I trial in Solid tumours (monotherapy) in Australia (NCT00569036)